Here we carried out a comparative study on two cost and time effective methods of encapsulating silver nanoparticles (AgNP) in dipalmitoyl-phosphatidyl choline (DPPC)/cholesterol-based liposome to enhance its cytotoxicity and reduce cytotoxic concentrations and evaluated the effect of this on a blood cell line (THP1 monocytes) often involved in uptake of nanoparticles during human exposure. DLS and Zeta potential analyses over a 6-months period showed the extruded Lipo-AgNP (ExLipo-AgNP) exhibited more stable characteristics when compared with the probe-sonicated Lipo-AgNP (PB-Lipo-AgNP). SEM microscopy indicated agglomeration of the PB-Lipo-AgNP which was not observed in Ex-Lipo-AgNP. Ex-Lipo-AgNP also exhibited higher temperaturedependent stability with 35.3% reduction in size from 20 C to 37 C while PB-Lipo-AgNP was less stable exhibiting 55% size reduction over same temperature range. Load release study over 24 h showed a controlled load release from Ex-Lipo-AgNP while the PB-Lipo-AgNP exhibited burst release at pH 4 and 6.5. Interestingly, it was found that Ex-Lipo-AgNP induced significantly higher toxicity on THP1 cell line after 24 h exposure compared with control unexposed cells; uncoated AgNP and PB-Lipo-AgNP exposed cells at the same concentration. Thus, for the first time, we report that liposomal encapsulation of AgNP by extrusion produces a stable nanocapsule with enhanced cytotoxicity, thus preventing overreliance on high AgNP concentration to achieve desired toxicity.
Introduction
Silver nanoparticles (AgNP) are a widely used nanoparticle for its antibacterial activities and many of the already commercialized products contain AgNP in high concentrations as the active ingredient. For example, AgNP is widely used as antibacterial coating on medical garments and surgical equipment and even on food materials to prolong shelf life by preventing food degradation consequent upon bacterial metabolism and growth [1, 2] . In addition, AgNP are currently being investigated by different studies as a chemotherapeutic in cancer treatment [3] [4] [5] [6] . Unfortunately, with the rise in the biomedical applications of AgNP, development of adverse conditions due to repeated human exposure to AgNP is imminent either from direct contact with products containing AgNP or AgNP that has leached into the ecosystem. AgNP has been reported to cause several adverse effects such as skin irritation and discoloration, hepatotoxicity, kidney damage, DNA damage and epithelia cell damage [7] .
Adverse reactions of conventional drugs are not uncommon and improvement on the delivery mechanisms has been a major way to limit these setbacks. For AgNPs however, there has been little or no research into how to improve upon the delivery mechanism to enhance their antibacterial or anticancer activities. The applications of liposomes in drug delivery systems (DDS) have been studied for more than two decades and there have been significant improvements in the formulations and methods by which liposome are prepared. For instance, phosphatidyl choline (PC) based lipids are highly used in liposome preparation likely due to the fact that PC makes up about 80% of the surfactants found on epithelial lining of human airways and lungs. Interestingly, the majority of the PC in the human airways is present in the form of dipalmitoylphosphatidyl choline (DPPC), and this makes up about 60% of the natural surfactants found in the human airways and lungs [8] . Consequently, DPPC is highly unlikely to elicit immune response when incorporated in a liposomal formulation compared to the other derivatives.
Liposomes are designed to mimic the lipid bilayer of the cell membrane and while the natural bilayer of the cell membrane is made up different phospholipids, they also contain cholesterol molecules that help restrict the movement of the fluid phospholipid molecules. In the same manner, it has been shown that cholesterol, when incorporated in liposomal formulations at the right concentration can produce such rigidity to protect the liposomal content [9] . In this study, AgNP synthesized by chemical reduction of silver nitrate (AgNO 3 ) using sodium borohydride (NaBH 4 ) was encapsulated in a DPPC/cholesterol liposome to both stabilize and improve the uptake of the AgNP in vitro for enhanced cytotoxicity. Two simple encapsulation methods were trialed AgNP, followed by nanoparticle characterization and evaluation of cytotoxicity on a THP1 cell line, a monocytic cell line which acts as first line of Defense against nanoparticle during exposure [10] .
Materials and methods

Chemicals and reagents
Silver nitrate (AgNO 3 ), sodium borohydride (NaBH 4 ), DPPC, cholesterol, Phorbol 12-myristate 13-acetate (PMA) and propidium iodide (PI) were purchased from Sigma Aldrich, Dublin, Ireland while chloroform, Calcein-AM dye and Alamar blue (AB) were from ThermoFischer Scientific, Dublin, Ireland.
AgNP synthesis
To synthesize AgNP, 6 mL of 1 mM of AgNO 3 solution was added dropwise into an Erlenmeyer flask containing magnetic stirrer a 350 rpm and ice cold 30 mL of 2 mM of NaBH 4 . The stirring was continued until last drop when the stirrer was removed for the solution to turn golden yellow. The obtained AgNP was characterized by UV/Vis in a Spectramax M2 microplate reader while atomic absorption spectrophotometry (AAS) was employed to monitor silver (Ag) concentration using a SpectrAA200 Varian Spectrophotometer (Mulgrave, VC, Australia). The samples were analyzed with a silver hollow cathode lamp at an operating current of 7.5 mA. Hydrodynamic size of AgNP and liposomal AgNP (Lipo-AgNP) was carried out with Malvern Zetasizer Nano ZS (Malvern Panalytical, Malvern, UK). Nanoparticles were loaded into a prerinsed folded capillary cell up to the marked portion. For zeta potential, an applied voltage of 15 and 50 V was used for Lipo-AgNP and free AgNP respectively.
Liposome synthesis, AgNP encapsulation and characterization
Liposome was prepared by probe sonication and extrusion methods. DPPC and cholesterol were weighed in a mass ratio such that eventual rehydration of the lipid film obtained will give a 7:3 molar ratio solution respectively. The lipids were dissolved in a fixed amount of chloroform and mixed until the mixture becomes clear. The resulting solution was placed in a vacuum oven set at 52 C for the chloroform to evaporate.
Probe sonication method
The lipid cake formed was then rehydrated in AgNP solution at 60 C. AgNP solution were added to the lipid at 1:300 (w/w) of AgNP:DPPC after which the solution was vortexed briefly for 2 min to form multi-lamellar vesicles (MLV). The mixture was probe sonicated at 21% amplitude, 20 s run and 20 s pause for 4 cycles to form Small Uni-lamellar Vesicles (SUV). The resultant mixture was then centrifuged at 800 Âg for 10 min at 4 C to remove any MLVs. The suspension was subjected to DLS and zeta potential analysis for size and stability measurements respectively.
Extrusion method
The lipid film was rehydrated in AgNP solution at 60 C to make the final concentration at 1:300 (w/w) of AgNP:DPPC. The solution was placed in the shaker at 60 C on 140 rpm for another 20 min after which it was vortexed briefly for 2 min to form multi-lamellar vesicles (MLV). This was then extruded through a 100 nm "Nanosizer" polycarbonate extruder purchased from T&T Scientific (Knoxville, USA). The suspension was subjected to DLS and zeta potential analysis for size and stability measurements respectively. 15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73   174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232 2.4. Temperature-dependent size measurements, stability tests and pH-dependent drug release study
To check the effect of incubation conditions on the nanocapsules, both probe-sonicated (PB-Lipo-AgNP) and Ex-Lipo-AgNP were subjected to temperature dependent size stability tests. This was done by preparing a solution Lipo-AgNP in 10% fetal bovine serum (FBS) supplemented RPMI-1640 and subjecting them to DLS size measurements over a temperature range of 20 C-38 C with 1 C increments of temperature. For nanoparticle stability determination, variations in nanoparticles mean size and zeta potential of both Ex-Lipo-AgNP and PB-Lipo-AgNP were measured at a specific interval over a period of 6 months at both 4 C (storage temperature) and 24 C (room temperature). 5 mL of PB-Lipo-AgNP and Ex-Lipo-AgNP were incubated at 4 C and 24 C and 1 mL sample was taken at each time point for analyses at specific time interval.
For pH dependent AgNP release from the nanocapsules, 1 mL of the encapsulated AgNP was added into a FLOAT-A-LYZER G2 CE dialysis tube with a 1000 KDa MW cut off (Spectrum Labs, Breda, Netherlands). The dialysis tube was placed in 6 mL of either an acetate buffer (pH 6.5) or a phosphate buffer saline (PBS) at pH 7.45. The ratio between the inside and outside volumes were maintained as thus to facilitate easy movement of the AgNP as recommended by Shen and Burgess [11] . The tube was then placed on a shaker running a 300 rpm at 37 C. To measure the amount of AgNP released, 200 mL of Lipo-AgNP sample was taken from the dialysis tube at specific time interval for 24 h and the absorbance was measured in the SpectraMax M2 microplate reader at 405 nm. After absorbance measurement, the measured sample was replaced with a fresh buffer to avoid change in volume and sink condition.
Scanning electron micrograph (SEM) and scanning transmission electron micrograph (STEM) analysis
SEM micrographs were obtained for both AgNP and Lipo-AgNPs. Briefly, both PB-Lipo-AgNP and Ex-Lipo-AgNP were microscopically analyzed using Hitachi SU-6600 field emission SEM (Hitachi, Maidenhead, UK) with accelerating voltage of 25 kV and 8 mm working distance. At 24 h before analysis was carried out, 5 mL of sample was drop-cast to air dry onto a 5 Â 5 mm pure silicon wafer substrate (Ted Pella Inc., Redding, California, USA) for SEM or carbon formvar copper grid (Agar Scientific Ltd., Stanstead, UK) for STEM, before micrographs were obtained.
Estimating encapsulation efficiency of the liposome
To estimate the encapsulation efficiency, both probe-sonicated and extruded Lipo-AgNP were centrifuged at 20,000 Â g for 1 h and the supernatant was harvested. The supernatant was then analyzed by atomic absorption spectrophotometry to estimate the concentration of silver in the solution. The encapsulation efficiency (E) of the liposome was then calculated using the formula below E ¼ Total AgNP added to liposomeÀAgNP in supernatant Total AgNP added to liposome Â 100 2.7. Cell culture and alamar blue cell viability THP1 (ATCC V R : TIB-202 TM ) used for this study were cultured in RPMI-1640 media supplemented with 2 mM L-glutamine and 10% FBS. The cells were incubated at 37 C, 95% humidity and 5% CO 2 . For nanoparticle exposure, cells were seeded in a 24-well plate (VWR, Dublin, Ireland) at a density of 3 Â 10 5 cells/mL in media containing 100 ng/mL PMA for a 24 h to induce adherence to the plate. After this, the culture media containing PMA was removed from the now adhered monocytic THP1 cells and replaced with fresh RPMI media containing different concentrations of uncoated AgNP, PB-Lipo-AgNP and Ex-Lipo-AgNP. A positive kill control of cells exposed to dimethyl sulfoxide (DMSO) solution (10% v/v) in RPMI media incorporated onto the plate. A minimum of three independent experiments were conducted and for each independent experiment, four replicate wells were employed per concentration per plate.
To evaluate cell viability post-exposure a pre-warmed 10% AB solution in serum free media was prepared. The exposure media were removed, and the cells were rinsed with prewarmed sterile 1 Â phosphate buffer saline (PBS) after which 1.5 mL of AB solution was added onto the cells and incubated at 37 C for 2 h. The resulting florescence of the converted AB dye was measured at 540 nm excitation and 595 nm emission and excitation wavelengths in a SpectraMax V R M2 Multi-Mode Microplate Reader.
Flow cytometry
THP1 cells were seeded and cultured in T25 flasks at 2 Â 10 5 cells/mL and were subsequently treated with 2 mg/ mL of free uncoated AgNP, PB-Lipo-AgNP or Ex-Lipo-AgNP for 24 h. As a positive kill control, THP1 cells exposed to 10% DMSO was also incorporated. After nanoparticle exposure, the cells were harvested into 15 mL tubes and were centrifuged at 300 Â g for 5 min at 21 C. The supernatant was discarded while the pellets were resuspended and rinsed twice in 2 mL prewarmed 1 Â PBS and centrifuged. The cells were then resuspended in 1 mL binding buffer containing 0.1% NaN 3 and 1% bovine serum albumin (BSA) solution in 1 Â PBS. The cells were double stained with 5 mL of 1 mM calcein-AM stain and 10 mL of 10 mg/mL PI and incubated in the dark at RT for 30 min and analyzed with a BD Accuri C6 flow cytometer.
Confocal microscopy
THP1 cells were seeded onto a confocal dish (VWR, Dublin Ireland) at density of 3 Â 10 5 cells/mL. The cells were also stimulated with 100 ng/mL of PMA for 24 h and subsequently treated with RPMI media containing 2 mg/mL of either PB -33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91   292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350 Lipo-AgNP and Ex-Lipo-AgNP for 24 h. Dish containing cells exposed to 0.5 nM doxorubicin were incorporated as positive kill control. After exposure, the media were discarded, and the cells were rinsed with pre-warmed sterile PBS. The cells were stained with 50 mL of 1 mM calcein-AM and 50 mL of 10 mg/ mL PI. The cells were then incubated in the dark at RT for 20 min and rinsed with warm PBS afterwards. Prior to imaging, 1 mL of warm PBS was added onto the cells and imaging was carried out with Zeiss LSM 510 Confocal Laser Scanning Microscope using a Plan-Neofluor oil immersion lens at 40 Â magnification and 1.3 numerical aperture.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism version 7. Data was analyzed by Two-way analysis of variance (ANOVA) with Sidak or Turkey multiple comparisons test to detect significance. Statistically significant differences in tests were indicated for p value < 0.05.
Results
DLS characterization
Results of the DLS characterization of AgNP is summarized in Table 1 for dispersions in water (ddH 2 O) and RPMI-1640 culture media. DLS analysis of AgNP shows an increase in mean particle size (MPS) of AgNP when dispersed in ddH 2 O to RPMI-1640 media from 21.14 nm to 79.15 nm with polydispersity index (PDI) 0.230-0.566 respectively. The zeta analysis for AgNP in ddH 2 O was À26.5 mV which dropped to À7.90 mV in RPMI-1640 media. There was also change in AgNP color from golden yellow in ddH 2 O to dark gray when dispersed in RPMI-1640 media which is likely due to agglomeration of the nanoparticle.
SEM/STEM and spectra analysis of AgNP
SEM analysis of the AgNP showed a spherical nanoparticle with average size of 14.3 ± 1.9 nm ( Figure 1A) . The UV-Vis spectra of the different AgNP concentration ranging from 0.625 to 10 mg/mL are depicted in Figure 1B , showing a characteristic peak absorption (kmax) corresponding to the surface plasmon resonance (SPR) of 20 nm AgNP at around 400 nm, which was the approximate size obtained by DLS. The peak flattening corresponds to decrease in concentration of AgNP, explained by the reduction in the amount of AgNP particles that absorbs UV light at the wavelengths indicated.
Liposome characterization
PB-Lipo-AgNP size increased from 143.7 when in ddH 2 O to 268.7 nm after dispersion in RPMI-1640 media ( Table 1) . A second peak of larger sized particles was observed in both ddH2O (1.3%) and RPMI media (19.6%) likely due to agglomeration. The PDI of PB-Lipo-AgNP also increased 51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  00  01  02  03  04  05  06  07  08  09   410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467 468 from 0.305 to 0.437 after resuspension in RPMI-1640 media but there was a reduction in zeta potential from À25.9 mV in ddH 2 O to À0.96 after dispersion in RPMI-1640 media. For Ex-Lipo-AgNP, there was a small decrease in size from 140.1 nm in ddH 2 O to 138.9 nm (half that of PB-Lipo-AgNP) when dispersed in RPMI-1640 media. Unlike the PB-Lipo-AgNP, extrusion produced Lipo-AgNP that was 100% uniform in size in ddH 2 O, however, a second peak was found at 3.9 mm for 14% of the particles in RPMI media ( Table 1 ). In contrast, Ex-Lipo-AgNP had a PDI of 0.105 in ddH 2 O but this increased to 0.421 in RPMI-1640 media. There was also a reduction in zeta potential of Ex-Lipo-AgNP from À31.9 mV in ddH 2 O, higher than that of PB-Lipo-AgNP to À0.61 mV in RPMI-1640.
An overlay of DLS size values of the uncoated AgNP in ddH 2 O was carried out with the size values of the PB-Lipo-AgNP obtained with the same AgNP solution both in ddH 2 O and in RPMI media ( Figure 2C ). Overlap in AgNP size value with that of the PB-Lipo-AgNP dispersed in ddH 2 O was observed, indicating some of AgNP had not been encapsulated within the PB-Lipo-AgNP. In addition, a shift in the major peak of the PB-Lipo-AgNP was observed for a 120 nm increase in size from dispersion in ddH 2 O to RPMI, accounting for 20% of the total nanoparticle. Ex-Lipo-AgNP exhibited no overlap with AgNP in both dispersion media, indicating both nanoparticles have distinct populations ( Figure 2D ). In addition, there was only a single peak observed for Ex-Lipo-AgNP dispersed in ddH 2 O indicative of uniform nanoparticle although there was a slight shift in the major peak to the left as the size reduced by 1.2 nm while a second peak was also visible, accounting for 14% of the total nanoparticle likely due to agglomeration in RPMI.
UV-Vis spectra analysis of encapsulated AgNP and encapsulation efficiency
Different concentrations of PB-Lipo-AgNP and extruded AgNP, were analyzed by UV-Vis spectra to investigate whether the AgNP has been successfully encapsulated ( Figures 3A and 3B ). PB-Lipo-AgNP showed a similar spectra characteristic with AgNP especially at 10 mg/mL but there was a red shift in the AgNP peak at around 410 nm, observable for both 5 mg/mL and 10 mg/mL. There was considerable peak flattening at concentration 5 mg/mL ( Figure 3A) . It was observed that PB-Lipo-AgNP was cloudy with lipids and retained the golden yellow color of AgNP showing presence of free AgNP (Figure 2A inset) . On the contrary for Ex-Lipo-AgNP, the peak absorbance was barely observed even at 10 mg/mL and there was also a red shift in the peak at around 410 nm ( Figure 3B ). Ex-Lipo-AgNP solution was clear and did not retain the golden yellow color of AgNP ( Figure 2B inset), likely because of the refraction due to the lipid layer of the liposome. PB-Lipo-AgNP also had higher absorbance compared to Ex-Lipo-AgNP (at 10 mg/mL) which has similar baseline with uncoated AgNP (Figure 3C ), indicating no agglomeration of Ex-Lipo-AgNP. The EE was determined to be 67.8% and 86.5% for the PB-Lipo-AgNP and Ex-Lipo-AgNP respectively, which may explain the similarities between the UV-Vis spectra of free AgNP and PB-Lipo-AgNP since less AgNP was encapsulated.
69 70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  00  01  02  03  04  05  06  07  08  09  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27   528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584 585 586 Table 1 . PB-Lipo-AgNP size reduced from 334 nm at 20 C to 150.2 nm, a 55% reduction in size at 37 C. For Ex-Lipo-AgNP, a reduction from 174.7 nm at 20 C to 113.1 nm at 37 C, a 35.3% reduction in size was observed ( Figure 4B ). This reduction in size could be as result of loss of liposomal content due to increase in temperature. Stability analyses of the liposomes over a 6-month period is shown in Table 2 . After 6 months of incubation, the MPS and zeta potential of PB-Lipo-AgNP increased by 10.3 nm and 5.1 mV respectively at 4 C. Compared to 4 C, PB-Lipo-AgNP at 24 C exhibited a higher reduction in MPS and zeta potential of 19 nm and 4.3 mV for the 6 months in addition to the sedimentation of the lipids that was observed. On the contrary, Ex-Lipo-AgNP showed slight increase in size as well as zeta potential over the 6-month period. At 4 C, an overall 3.2 nm and 2.0 mV MPS and zeta potential was observed, which was comparable to that observed at 24 C (5.9 nm and 2.5 mV MPS and zeta potential respectively), and lower to that of PB-Lipo-AgNP for the same time points.
The load release profile of both Lipo-AgNPs was carried out to evaluate AgNP release from the nanocapsule using dialysis. Due to the large volume of fluid outside the dialysis tube and the effect this will have on the absorbance of minute quantity of released nanoparticles from the dialysis 87  88  89  90  91  92  93  94  95  96  97  98  99  00  01  02  03  04  05  06  07  08  09  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43 44 45 tube, the absorbance of the sample inside of the dialysis tube was measure instead, as drop in absorbance will corresponds to the amount of AgNP released into the buffer. As shown in Figure 5A , PB-Lipo-AgNP appeared to have initial burst release of AgNP as more than 25% of the encapsulated AgNP was released within the first 2 h at pH 6.5. Afterwards, a release of 29% to 30% at 4 and 6 h respectively was observed. Unlike PB-Lipo-AgNP, the extruded AgNP showed a steady release from 2 h up till 6 h, releasing only 15% of the encapsulated AgNP at 6 h, a significantly lower release to that of PB-Lipo-AgNP. Both nanocapsules exhibited similar release at 24 h with PB-Lipo-AgNP releasing 80% of encapsulated AgNP while Ex-Lipo-AgNP released 74%. At physiological pH of 7.45, PB-Lipo-AgNP exhibited lower release rate of AgNP from 2 h to 6 h releasing 0.8% to 12.5% respectively. In the same time point, Ex-Lipo-AgNP only released 0.7% to 3.5% respectively, a significantly lower release than that of PB-Lipo-AgNP. At 24 h, Ex-Lipo-AgNP released 70%, a significantly lower release compared with PB-Lipo-AgNP exhibiting 79% AgNP release ( Figure 5B ).
Cell viability
To evaluate if the stability of Ex-Lipo-AgNP translates to enhanced cytotoxicity, THP1 cells were first stimulated with 100 ng/mL PMA to induce adherence of the cell line prior to exposure to facilitate easy removal of uninternalized liposome and prevent cell loss during wash steps. After 24 h of exposure to the nanoparticles, viability of the PMA-stimulated THP1 cells was evaluated by their ability to convert the non-fluorescent resazurin in AB dye into a fluorescent resorufin. As shown in Figure 6A 05  06  07  08  09  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63   764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818 819 820 821 822 significant reduction in the THP1 cell viability at 5 mg/mL. It was observed that Ex-Lipo-AgNP at concentrations of 1.25 and 2.5 mg/mL were significantly more cytotoxic on THP1 cell than the PB-Lipo-AgNP at the same concentration.
A flow cytometry cell viability study was carried out to confirm AB finding since flow cytometry is a more accurate analyses of viability on a cell by cell basis. THP1 monocytes exposed to AgNP, PB-Lipo-AgNP and Ex-Lipo-AgNP were stained with calcein-AM and PI. Calcein-AM is a non-fluorescent stain hydrolyzed by esterase activity of viable cell into a fluorescent calcein derivative that is maintained within cell with intact cell membrane [12] , while PI only permeates compromised membrane of dead cells. As expected, Ex-Lipo-AgNP induced significantly more cell death compared to free AgNP and PB-Lipo-AgNP (p < 0.001). A significantly higher proportion of early apoptotic cells positive for both calcein and PI (9.7%) and late apoptotic cells that are only positive for PI (26.4%) was observed in Ex-Lipo-AgNP exposed cells compared to unexposed control cells, free AgNP and PB-Lipo-AgNP exposed groups ( Figure 6B ). In addition to this, PB-Lipo-AgNP exposure resulted in higher proportion of cells identified as cellular debris (22.6%) compared to Ex-Lipo-AgNP (1.1%) which was similar to that in untreated controls and free AgNP exposed cells (0.2%) (p < 0.001). This cell population are likely due to PB-Lipo-AgNP identified as cellular debris due to the larger and ununiform sizes.
To further confirm the effect of the Lipo-AgNPs on cell viability, confocal microscopy was used to analyze calcein-AM and PI stained PMA-stimulated THP1 cells exposed to nanocapsules containing equivalent amount of 2 mg/mL AgNP for 24 h. THP1 cells that were exposed to either of PB-Lipo-AgNP or Ex-Lipo-AgNP appeared to have spotted calcein fluorescence ( Figures 7A and 7B ). This was unlike the control-untreated THP1 cells which appeared to have uniform calcein stain throughout the cytoplasm. In addition, only Ex-Lipo-AgNP induced significantly higher cytotoxicity on THP1 cells compared with control-untreated or PB-Lipo-AgNP exposed cells (p < 0.01) ( Figures 7A and 7B) . Similarly, only Ex-Lipo-AgNP resulted in significantly higher PI fluorescence when compared to both PB-Lipo-AgNP exposed and control-untreated cells (p < 0.001). Thus, verifying the result of the AB and flow cytometry assays.
Discussion
AgNP can be synthesized from AgNO 3 by different methods such as using reducing agents like citrate or NaBH 4 with further stabilization of the nanoparticle with compounds such as polyvinyl alcohol (PVA) [13] [14] [15] . A citrate-based reduction is most commonly used in the synthesis of AgNP because of its reducing and stabilizing functionality. However, reduction of AgNO 3 with citrate results in formation of AgNP in complex with the citrate ions which prevents the release of elemental 23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81   882  883  884  885  886  887  888  889  890  891  892  893  894  895  896  897  898  899  900  901  902  903  904  905  906  907  908  909  910  911  912  913  914  915  916  917  918  919  920  921  922  923  924  925  926  927  928  929  930  931  932  933  934  935  936  937  938 939 940 Figure 6 . Cell viability of PMA-stimulated THP1 cells post-exposure to AgNP nanocapsules: (A) AB assay determining viability of PMA-stimulated THP1 cells exposed to 0.3-5 mg/mL AgNP, PB-Lipo-AgNP and Ex-Lipo-AgNP for 24 h (B) unstimulated THP1 monocytes cell viability by flow cytometry after exposure to 2 mg/mL of AgNP, PB-Lipo-AgNP and Ex-Lipo-AgNP. Calcein was assessed on FL-1 channel while PI was assessed in the FL-3 channel. Data is presented as mean ± SD of the three independent experiments and similar values were obtained. ÃÃÃ p < 0.001 and ÃÃÃÃ p < 0.0001. silver [16] , limiting its effects. We report here, the encapsulation of AgNP in a DPPC based liposome through different methods to enhance its associated cytotoxicity. The AgNP synthesis employed here was designed to yield elemental AgNP through reduction of AgNO 3 by NaBH 4 as in the equation below;
One of the aims of this study was to encapsulate AgNP in a DPPC liposome, as DPPC is a natural biosurfactant in human airways. Thus, it is hoped that such a system will result in a very low capability of inducing adverse immune responses. SEM images of PB-Lipo-AgNP indicated a high agglomeration while that of Ex-Lipo-AgNP indicated a uniform spherical nanoparticle. In addition, DLS analyses indicated higher average size for PB-Lipo-AgNP compared to Ex-Lipo-AgNP both in ddH 2 O and RPMI media. It is believed that PB-Lipo-AgNP increased size could have significant impact on cellular response. It is known that larger nanoparticles have reduced bioavailability as they are quickly eradicated by the reticulo-endothelial system [17] , making PB-Lipo-AgNP less practical for in vitro applications as a drug delivery system. PB-Lipo-AgNP exhibited a lower zeta potential À25.9 mV while that of Ex-Lipo-AgNP was À31.9 mV. Nanoparticles with zeta potential value between À30 and þ30 mV are considered less stable owing to the increased agglomeration potential due to reduced repulsion between the particles [18] , indicating the Ex-Lipo-AgNP is more stable. In addition to this, the PDI of PB-Lipo-AgNP was found to be higher than that of Ex-Lipo-AgNP in ddH 2 O, indicating that Ex-Lipo-AgNP are of more uniform size compared to PB-Lipo-AgNP.
The UV-Vis spectra analysis of free AgNP conformed with reported SPR characteristic of a 20 nm AgNP which is at 400 nm [19] , in a way confirming the DLS size of 21 nm. UV-Vis spectra analysis of both PB-Lipo-AgNP and Ex-Lipo-AgNP also allude the success of the encapsulation process. PB-Lipo-AgNP and AgNP had a similar spectra profile with same kmax although PB-Lipo-AgNP spectra exhibited a broadened peak with a raised baseline and a red shift in the kmax, which are indicative of agglomeration/size increase. The kmax also indicates free AgNP that are not successfully encapsulated absorbing UV emission to produce the observed spectrum. In support of this, an overlap in the DLS size value of AgNP with the ddH 2 O dispersed PB-Lipo-AgNP observed indicates that the PB-Lipo-AgNP particles in 41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99 the overlap region is more likely to be uncoated AgNP. Contrastingly, Ex-Lipo-AgNP spectra depicted a flat peak with same baseline as free AgNP which hints at nonagglomeration of the nanoparticle. The spectra observed at 10 mg/mL was similar to that of 1.25 mg/mL of free AgNP indicating less free AgNP that are able to absorb at the UV-Vis wavelength. This observation is also supported by nonoverlap of the AgNP and Ex-Lipo-AgNP DLS size values.
Interaction between nanoparticles and culture media proteins is not uncommon based on their surface reactivity. This interaction was monitored through the size and zeta potential of the liposomes in RPMI-1640 medium. There was increase in the size of PB-Lipo-AgNP and drastic reduction in its zeta potential. The dramatic increase in PB-Lipo-AgNP size in RPMI-1640 could be due to the AgNP on the surface interacting with the proteins in the culture medium as also observed for free AgNP. This is in agreement with the findings of Sabuncu et al. [20] who also reported an increase in gold nanoparticle size and decrease in the zeta potential when dispersed in fetal calf serum (FCS) supplemented DMEM culture. This is supported by the DLS overlay of PB-Lipo-AgNP in ddH 2 O and RPMI which indicates increase in size of the nanoparticle from dispersion in ddH 2 O to RPMI medium. On the contrary, there was a considerable drop in the zeta potential of Ex-Lipo-AgNP, with only a small increase in the percentage of nanoparticles with increased size (14%). This could mean that Ex-Lipo-AgNP do not readily react with proteins in the culture medium, resulting in no net increase in the size after dispersion in FBS containing RPMI-1640 medium. Interestingly, the charges on the protein amino acids may have a masking effect on Ex-Lipo-AgNP zeta potential. The spectra characteristic of Ex-Lipo-AgNP was less similar to that of AgNP, although with a red shift in kmax at 410 nm. Taken together with the similar baseline as free AgNP and the low absorbance at kmax which is about 50% less than that of free AgNP and PB-Lipo-AgNP, the shift is likely due to the increase in size contributed by the liposome. This also shows that the AgNP is bound to the liposome assuming a larger size than prior to encapsulation such that less AgNP particles are available to interact with proteins in the RPMI media and absorb UV emission. In a study investigating the use of AgNP as biosensor, a red shift in the spectra of a 19 nm AgNP was reported to be consequent upon the binding of the nanoparticle to protein ligands present on the biosensor platform [21] , explaining why there was no considerable change in the Lipo-AgNP size in the media.
In temperature dependent study, it was noted that the PB-Lipo-AgNP size decreased by more than half at 37 C whereas Ex-Lipo-AgNP only decreased in size by about a quarter of the original size. The reason for reduction in their sizes with increased temperature is not known, but this could be as a result of the increased fluidity of the lipid bilayer at temperature close to the transition temperature. Increased fluidity could result in the movement of the liposomal water content out of the liposome into the more concentrated culture medium by osmosis. A previous report indicated liposome often lose their aqueous content when dispersed in medium of high osmolarity [22] , such that water moves from region of lower concentration to region of higher concentration through the lipid bilayer. As such, Ex-Lipo-AgNP appeared to be more stable with respect to its ability to retain its content at 37 C. The stability study over a 6-months period also indicated Ex-Lipo-AgNP to be more stable with minimal overall increase in size and zeta potential at both 4 C and 24 C compared to PB-Lipo-AgNP which was also found to sediment unlike the Ex-Lipo-AgNP that remained clear.
Encapsulation of AgNP in liposome here was carried out with the intent of improving its cytotoxicity as a chemotherapeutic agent. Hence, it became pertinent to carry out drug release studies. Considering the possible route of administration and target site for the encapsulated AgNP, pH of 7.45 which is the physiologic pH and most culture media (relevant for in vitro studies) and pH 6.5 which is known to be the pH of the tumor microenvironment and inflamed tissue [23] [24] [25] , were considered. One of the major problems associated with drug delivery systems is the initial burst release which is associated with an initial hypertoxicity and suboptimal concentration of the drug at the time it reaches the target. A good drug delivery system is expected to protect the drug against the harsh physiological environment of immune cells, minimize the burst release and maintain a steady release of the drug for optimal concentration to achieve maximum efficacy over a period. Findings in this study, showed that PB-Lipo-AgNP possesses initial burst release at pH 6.5 and 7.45. Ex-Lipo-AgNP exhibited and maintained a steady release of AgNP at pH 6.5 with significantly lower release compared to PB-Lipo-AgNP. At 24 h, the two systems have released similar concentration of AgNP. At physiologic pH of 7.45, PB-Lipo-AgNP had already released 12.5% of the encapsulated AgNP compared to 3.5% of Ex-Lipo-AgNP. Initial burst release has been demonstrated for Ag þ coated with titanium dioxide used as an antibacterial for Staphylococcus aureus [26] . Although it was found that this rapid release produced an effective antibacterial effect, this effect can be quite adverse in an in vivo model.
Initial burst release has been proposed to occur consequent upon rapid dissolution of weakly or poorly encapsulated drugs that might be attached to the surface of the delivery systems [27] [28] [29] [30] . This supports our deduction from UV/Vis spectra features of PB-Lipo-AgNP to weakly encapsulate AgNP with some free AgNP attached to the surface of the liposome as also depicted in the STEM image. Contrastingly, our finding indicated that Ex-Lipo-AgNP can maintain steady AgNP release at both pH 6.5 and 7.45. The advantage is that the absence of initial burst release of Ex-Lipo-AgNP prevents initial hypertoxicity. On the other hand, while Ex-Lipo-AgNP had significantly less drug release at 24 h compared with PB-Lipo-AgNP at pH 7.45, stability of Ex-Lipo-AgNP may facilitate better drug delivery with better net cytotoxicity. In support of the finding for Ex-Lipo-AgNP however, Ruttala and Ko [31] , showed that a liposomal anti-tumor agent with steady load release exhibited enhanced cytotoxicity.
The uncertainty that encapsulation of AgNP translates to enhanced and improved cytotoxicity led to the investigation of the cytotoxicity of PB-Lipo-AgNP and Ex-Lipo-AgNP on THP1, a leukemic cell line in the monocytic lineage. The choice of the cell line for this study is three-folds. Firstly, THP1 is a leukemic (cancer) cell line, allowing investigation of the cytotoxic effect of AgNP encapsulation on a cancer cell line. Secondly, monocytes and similar immune cells act as first line of Defense in response to foreign objects including nanoparticles upon human exposure [32] [33] [34] , making the cell line a perfect model to also study the effect of the nanoparticle on the innate immune system. In addition to this, due to the role of monocytes in diseases such as atherosclerosis and cancer [35] , this cell line is a potential therapeutic target in treatment of this diseases.
Upon exposure of THP1 monocytes to the different nanoparticles, it was discovered that Ex-Lipo-AgNP induced significantly higher cytotoxicity at lower concentrations compared with PB-Lipo-AgNP and free uncoated AgNP exposed cells. In addition, flow cytometry and confocal microscopy analyses both confirmed Ex-Lipo-AgNP to be more cytotoxic compared to PB-Lipo-AgNP and free uncoated AgNP. There was a significantly higher live cells and less dead cells in the controluntreated, free uncoated AgNP, and PB-Lipo-AgNP exposed cells groups compared to Ex-Lipo-AgNP exposed cells. Another observation was the speckled fluorescence observed in both PB-Lipo-AgNP and Ex-Lipo-AgNP exposed cells but not the control-untreated cells. This is likely due to the loss of membrane integrity upon exposure to the nanoparticles resulting in leakage of calcein from the cytoplasm. Foged et al. [36] have previously showed that disruption of the cell membrane can result in leakage of calcein.
The enhanced cytotoxicity of Ex-Lipo-AgNP in comparison to AgNP or PB-Lipo-AgNP may be attributed to its superior characteristics and enhanced delivery. This may have been facilitated by the hydrophobic interaction between the lipid bilayer of the cell membrane and that of the liposome encapsulating the AgNP. On the other hand, the slightly enhanced cytotoxicity of the PB-Lipo-AgNP may be because of less encapsulated AgNP and lower endocytosis due to larger size in culture media. This reason may also explain why Ex-Lipo-AgNP enhanced delivery into the cells since its size may have remained unchanged even when reconstituted in culture media. Lastly, flow cytometry detected more cellular debris in PB-Lipo-AgNP exposed THP1 cells than in other exposure groups. These debris were due to the PB-Lipo-AgNP which were larger in size and similar to left over of apoptosed cells. Unfortunately, this identified debris are counted as events in the cytometer, imposing a confounding effect on the number of viable cells that will be analyzed. Interestingly, Ex-Lipo-AgNP does not exhibit such anomaly, further alluding to the stability and superior characteristic liposome obtained through the extrusion as compared with that obtained from probe sonication. Taken together, encapsulation of AgNP in DPPC based liposome may help limit the concentration of AgNP used in the various biomedical applications to achieve better cytotoxicity resulting in less human exposure and mitigation of any development of adverse effects.
Conclusion
Stable AgNP were successfully synthesized at a suitable concentration without the need for stabilizer. Synthesized AgNP were successfully encapsulated in liposome for the first time by both probe sonication and extrusion methods. However, the extrusion method produced a more stable liposome both when dispersed in ddH 2 O and in culture medium. The spectra analysis confirms probe sonication produced a less successful encapsulation based on the similarity between PB-Lipo-AgNP and AgNP spectra characteristics. Ex-Lipo-AgNP on the other hand had a different spectra analysis which is believed to be as a result of the shielding effect of the liposome bilayer. In addition, Ex-Lipo-AgNP exhibited a more controlled AgNP release compared with the PB-Lipo-AgNP which showed an initial burst release. Cell viability studies indicated that Ex-Lipo-AgNP exhibited higher cytotoxic effect in comparison to PB-Lipo-AgNP and uncoated AgNP at similar concentrations. This may have been due to the stable characteristic of Ex-Lipo-AgNP facilitating an effective delivery of the nanoparticle into the cell. As such, extrusion method offers a more reliable way for encapsulating AgNP in liposome with repetitive characteristics and enhanced cytotoxicity. This provides with potential of achieving cytotoxicity at lower concentrations compared to those currently in application limiting possible exposures.
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